Measurement of non-VKA oral anticoagulants versus classic ones: The appropriate use of hemostasis assays

Thrombosis Journal

Volumn 12, Issue 1, 2014, Pages

  Douxfils, Jonathan ^a   Tamigniau, Anne ^b   Chatelain, Bernard ^b   Goffinet, Catherine ^c   Dogné, Jean Michel ^a   Mullier, François ^a,b  

^a University of Namur   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c Clinique & Maternite Sainte Elisabeth Namer   (Belgium)

Author keywords

Apixaban; Dabigatran; Enoxaparin; Low molecular weight heparin; Monitoring; Non VKA oral anticoagulants; Rivaroxaban; Vitamin K antagonist

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN ETEXILATE; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HEPARIN CALCIUM; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; RIVAROXABAN; TINZAPARIN; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BIOLOGICAL MONITORING; BLEEDING; BLOOD CLOTTING TEST; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; GESTATION PERIOD; HEART INFARCTION; HUMAN; KIDNEY FAILURE; LABORATORY TEST; LUNG EMBOLISM; META ANALYSIS (TOPIC); OBESITY; PARTIAL THROMBOPLASTIN TIME; PHASE 3 CLINICAL TRIAL (TOPIC); POINT OF CARE TESTING; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM;

EID: 84928240024     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-12-24     Document Type: Review

References (195)

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361: 1139-1151. 10.1056/NEJMoa0905561.
2. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365: 883-891. 10.1056/NEJMoa1009638.
3. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365: 981-992. 10.1056/NEJMoa1107039.
4. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J: Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013, 369: 2093-2104. 10.1056/NEJMoa1310907.
5. Investigators E, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH: Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363: 2499-2510.
6. Investigators E-P, Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366: 1287-1297.
7. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N: Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014, 129: 764-772. 10.1161/CIRCULATIONAHA.113.004450.
8. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE: Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013, 369: 799-808. 10.1056/NEJMoa1302507.
9. Hokusai VTEI, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L: Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013, 369: 1406-1415.
10. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F: Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008, 358: 2765-2775. 10.1056/NEJMoa0800374.
11. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap ÁF, Misselwitz F, Haas S: Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008, 372: 31-39. 10.1016/S0140-6736(08)60880-6.
12. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG, Investigators R: Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008, 358: 2776-2786. 10.1056/NEJMoa076016.
13. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ: Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009, 373: 1673-1680. 10.1016/S0140-6736(09)60734-0.
14. Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R: Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007, 5: 2178-2185. 10.1111/j.1538-7836.2007.02748.x.
15. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR: Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007, 370: 949-956. 10.1016/S0140-6736(07)61445-7.
16. Committee R-MW, Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE: Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009, 24: 1-9.
17. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ: Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011, 105: 721-729. 10.1160/TH10-10-0679.
18. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ: Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009, 361: 594-604. 10.1056/NEJMoa0810773.
19. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, Investigators A: Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010, 363: 2487-2498. 10.1056/NEJMoa1006885.
20. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P, Investigators A: Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010, 375: 807-815. 10.1016/S0140-6736(09)62125-5.
21. Turpie AG, Kreutz R, Llau J, Norrving B, Haas S: Management consensus guidance for the use of rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2012, 108: 876-886. 10.1160/TH12-03-0209.
22. Minet V, Bailly N, Douxfils J, Osselaer JC, Laloy J, Chatelain C, Elalamy I, Chatelain B, Dogne JM, Mullier F: Assessment of the performances of AcuStar HIT and the combination with heparin-induced multiple electrode aggregometry: a retrospective study. Thromb Res 2013, 132: 352-359. 10.1016/j.thromres.2013.06.004.
23. Mullier F, Minet V, Bailly N, Devalet B, Douxfils J, Chatelain C, Elalamy I, Dogne JM, Chatelain B: Platelet microparticle generation assay: a valuable test for immune heparin-induced thrombocytopenia diagnosis. Thromb Res 2014, 133: 1068-1073. 10.1016/j.thromres.2013.12.009.
24. Garg AX, Papaioannou A, Ferko N, Campbell G, Clarke JA, Ray JG: Estimating the prevalence of renal insufficiency in seniors requiring long-term care. Kidney Int 2004, 65: 649-653. 10.1111/j.1523-1755.2004.00412.x.
25. Hellden A, Odar-Cederlof I, Nilsson G, Sjoviker S, Soderstrom A, Euler M, Ohlen G, Bergman U: Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly. BMJ Open 2013, 3: e002686.
26. Maccallum PK, Mathur R, Hull SA, Saja K, Green L, Morris JK, Ashman N: Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study. BMJ Open 2013, 3: e003343.
27. Adcock DM, Kitchen SO JD, Preston EF: Sample Integrity and Preanalytical Variables. In Quality in Laboratory Hemostasis and Thrombosis. 2nd edition. John Wiley & Sons ed: Blackwell Publishing Ltd; 2013:45-56.
28. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD: Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC working group on thrombosis--task force on anticoagulants in heart disease. Thromb Haemost 2013, 110: 1087-1107. 10.1160/TH13-06-0443.
29. Kitchen S, Gray E, Mackie I, Baglin T, Makris M, the Bc: Measurement of non-coumarin anticoagulants and their effects on tests of haemostasis: guidance from the British committee for standards in haematology. Br J Haematol 2014. doi:10.1111/bjh.12975. [Epub ahead of print].
30. Altman R: New oral anticoagulants: are coagulation units still required? Thromb J 2014, 12: 3. 10.1186/1477-9560-12-3.
31. Contant G, Gouault-Heilmann M, Martinoli JL: Heparin inactivation during blood storage: its prevention by blood collection in citric acid, theophylline, adenosine, dipyridamole-C.T.A.D. mixture. Thromb Res 1983, 31: 365-374. 10.1016/0049-3848(83)90337-7.
32. Ray MJ, Carroll PA, Just SJ, Hawson GA: A low volume specimen container suitable for monitoring the aPTT of heparinized patients. Blood Coagul Fibrinolysis 1993, 4: 805-807. 10.1097/00001721-199310000-00020.
33. Juurlink DN: Drug interactions with warfarin: what clinicians need to know. CMAJ 2007, 177: 369-371. 10.1503/cmaj.070946.
34. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, American College of Chest P: Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133: 160S-198S. 10.1378/chest.08-0670.
35. Quick AJ: The thromboplastin reagent for the determination of Prothrombin. Science 1940, 92: 113-114.
36. Poller L, Keown M, Chauhan N, van den Besselaar AM, Tripodi A, Shiach C, Jespersen J: European concerted action on anticoagulation. A multicentre calibration study of WHO international reference preparations for thromboplastin, rabbit (RBT/90) and human (rTF/95). J Clin Pathol 2005, 58: 667-669. 10.1136/jcp.2004.019810.
37. Poller L, Thomson JM, Taberner DA, Clarke DK: The correction of coagulometer effects on international normalized ratios: a multicentre evaluation. Br J Haematol 1994, 86: 112-117. 10.1111/j.1365-2141.1994.tb03260.x.
38. Poller L, Jespersen J, Ibrahim S, European Action on A: Warfarin or dabigatran for treatment of atrial fibrillation. J Thromb Haemost 2014, 12: 1193-1195. 10.1111/jth.12590.
39. Poller L, Ibrahim S, Keown M, Pattison A, Jespersen J, European Action On A: The prothrombin time/international normalized ratio (PT/INR) line: derivation of local INR with commercial thromboplastins and coagulometers--two independent studies. J Thromb Haemost 2011, 9: 140-148. 10.1111/j.1538-7836.2010.04109.x.
40. van den Besselaar AM: Artificially depleted plasmas are not necessarily commutable with native patient plasmas for international sensitivity index calibration and international normalized ratio derivation. J Thromb Haemost 2012, 10: 303-305. 10.1111/j.1538-7836.2011.04582.x.
41. Ibrahim S, Jespersen J, Poller L, European Action on A: The clinical evaluation of International normalized ratio variability and control in conventional oral anticoagulant administration by use of the variance growth rate. J Thromb Haemost 2013, 11: 1540-1546. 10.1111/jth.12322.
42. Poller L, Keown M, Chauhan N, van den Besselaar AM, Tripodi A, Jespersen J, Shiach C: European concerted action on anticoagulation. Minimum numbers of lyophilized plasma samples for ISI calibration of CoaguChek and TAS point-of-care whole blood prothrombin time monitors. Am J Clin Pathol 2003, 119: 232-240. 10.1309/25BKYQEP6858GLFD.
43. Christensen TD, Larsen TB: Precision and accuracy of point-of-care testing coagulometers used for self-testing and self-management of oral anticoagulation therapy. J Thromb Haemost 2012, 10: 251-260. 10.1111/j.1538-7836.2011.04568.x.
44. DeSantis G, Hogan-Schlientz J, Liska G, Kipp S, Sallee R, Wurster M, Kupfer K, Ansell J: STABLE results: warfarin home monitoring achieves excellent INR control. Am J Manag Care 2014, 20: 202-209.
45. Heneghan C, Ward A, Perera R, Self-Monitoring Trialist C, Bankhead C, Fuller A, Stevens R, Bradford K, Tyndel S, Alonso-Coello P: Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012, 379: 322-334. 10.1016/S0140-6736(11)61294-4.
46. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P: Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006, 367: 404-411. 10.1016/S0140-6736(06)68139-7.
47. Jowett S, Bryan S, Murray E, McCahon D, Raftery J, Hobbs FD, Fitzmaurice D: Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis. Br J Haematol 2006, 134: 632-639. 10.1111/j.1365-2141.2006.06243.x.
48. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH, American College of Chest P: Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141: e152S-e184S.
49. Ufer M: Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005, 44: 1227-1246. 10.2165/00003088-200544120-00003.
50. Witt DM: Approaches to optimal dosing of vitamin K antagonists. Semin Thromb Hemost 2012, 38: 667-672.
51. Poller L, Keown M, Ibrahim S, Lowe G, Moia M, Turpie AG, Roberts C, van den Besselaar AM, van der Meer FJ, Tripodi A: A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program. Thromb Haemost 2009, 101: 487-494.
52. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, American College of Chest P: Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141: e44S-e88S.
53. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E: A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993, 69: 236-239.
54. Schulman S, Parpia S, Stewart C, Rudd-Scott L, Julian JA, Levine M: Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med 2011, 155: 653. -9, W201-3 10.7326/0003-4819-155-10-201111150-00003.
55. Clark NP: Frequency of monitoring, non-adherence, and other topics dear to an anticoagulation clinic provider. J Thromb Thrombolysis 2013, 35: 320-324. 10.1007/s11239-013-0887-y.
56. Rose AJ, Hylek EM, Berlowitz DR, Ash AS, Reisman JI, Ozonoff A: Prompt repeat testing after out-of-range INR values: a quality indicator for anticoagulation care. Circ Cardiovasc Qual Outcomes 2011, 4: 276-282. 10.1161/CIRCOUTCOMES.110.960096.
57. Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, Garcia DA, Ageno W, Hylek EM, Warped C: Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. J Thromb Haemost 2010, 8: 744-749. 10.1111/j.1538-7836.2010.03756.x.
58. Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, Garcia DA, Ageno W, Hylek EM, Warfarin Associated Research P, other EnDeavors C: Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood 2009, 114: 952-956. 10.1182/blood-2009-02-207928.
59. Rose AJ, Berlowitz DR, Miller DR, Hylek EM, Ozonoff A, Zhao S, Reisman JI, Ash AS: INR targets and site-level anticoagulation control: results from the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost 2012, 10: 590-595. 10.1111/j.1538-7836.2012.04649.x.
60. Sorano GG, Biondi G, Conti M, Mameli G, Licheri D, Marongiu F: Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients: a clinical practice proposal. Haemostasis 1993, 23: 77-82.
61. Kurnik D, Loebstein R, Rabinovitz H, Austerweil N, Halkin H, Almog S: Over-the-counter vitamin K1-containing multivitamin supplements disrupt warfarin anticoagulation in vitamin K1-depleted patients. A prospective, controlled trial. Thromb Haemost 2004, 92: 1018-1024.
62. Schurgers LJ, Shearer MJ, Hamulyak K, Stocklin E, Vermeer C: Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. Blood 2004, 104: 2682-2689. 10.1182/blood-2004-04-1525.
63. Reese AM, Farnett LE, Lyons RM, Patel B, Morgan L, Bussey HI: Low-dose vitamin K to augment anticoagulation control. Pharmacotherapy 2005, 25: 1746-1751. 10.1592/phco.2005.25.12.1746.
64. Sconce E, Khan T, Mason J, Noble F, Wynne H, Kamali F: Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost 2005, 93: 872-875.
65. Ford SK, Misita CP, Shilliday BB, Malone RM, Moore CG, Moll S: Prospective study of supplemental vitamin K therapy in patients on oral anticoagulants with unstable international normalized ratios. J Thromb Thrombolysis 2007, 24: 23-27. 10.1007/s11239-007-0014-z.
66. Rombouts EK, Rosendaal FR, Van Der Meer FJ: Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost 2007, 5: 2043-2048. 10.1111/j.1538-7836.2007.02715.x.
67. Sconce E, Avery P, Wynne H, Kamali F: Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007, 109: 2419-2423. 10.1182/blood-2006-09-049262.
68. Rombouts EK, Rosendaal FR, van der Meer FJ: Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy. Br J Haematol 2010, 149: 598-605. 10.1111/j.1365-2141.2010.08108.x.
69. Makris M, Watson HG: The management of coumarin-induced over-anticoagulation annotation. Br J Haematol 2001, 114: 271-280. 10.1046/j.1365-2141.2001.02908.x.
70. Hylek EM, Skates SJ, Sheehan MA, Singer DE: An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996, 335: 540-546. 10.1056/NEJM199608223350802.
71. Poller L, Jespersen J, Ibrahim S, Pattison A, European Action on A: Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a rebuttal. J Thromb Haemost 2013, 11: 1203-1205. 10.1111/jth.12164.
72. Dawes J, Bara L, Billaud E, Samama M: Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis 1986, 16: 116-122.
73. Hirsh J, Raschke R: Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004, 126: 188S-203S. 10.1378/chest.126.3_suppl.188S.
74. Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, Jackson S, Turpie AG, MacKinnon B, Hirsh J: Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006, 296: 935-942. 10.1001/jama.296.8.935.
75. Heit JA, Lahr BD, Petterson TM, Bailey KR, Ashrani AA, Melton LJ 3rd: Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. Blood 2011, 118: 4992-4999. 10.1182/blood-2011-05-357343.
76. Zehnder J, Price E, Jin J: Controversies in heparin monitoring. Am J Hematol 2012, 87: S137-S140. 10.1002/ajh.23210.
77. Basu D, Gallus A, Hirsh J, Cade J: A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972, 287: 324-327. 10.1056/NEJM197208172870703.
78. Garcia DA, Baglin TP, Weitz JI, Samama MM, American College of Chest P: Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141: e24S-e43S.
79. Bates SM, Weitz JI, Johnston M, Hirsh J, Ginsberg JS: Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Arch Intern Med 2001, 161: 385-391. 10.1001/archinte.161.3.385.
80. Gouin-Thibaut I, Martin-Toutain I, Peynaud-Debayle E, Marion S, Napol P, Alhenc-Gelas M: Monitoring unfractionated heparin with APTT: a French collaborative study comparing sensitivity to heparin of 15 APTT reagents. Thromb Res 2012, 129: 666-667. 10.1016/j.thromres.2011.11.016.
81. Bonar RA, Favaloro EJ, Marsden K: External quality assurance for heparin monitoring. Semin Thromb Hemost 2012, 38: 632-639.
82. Cuker A, Raby A, Moffat KA, Flynn G, Crowther MA: Interlaboratory variation in heparin monitoring: lessons from the quality management program of Ontario coagulation surveys. Thromb Haemost 2010, 104: 837-844. 10.1160/TH10-02-0099.
83. D'Angelo A, Seveso MP, D'Angelo SV, Gilardoni F, Dettori AG, Bonini P: Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT. Am J Clin Pathol 1990, 94: 297-306.
84. Marlar RA, Gausman JN: The effect of instrumentation and laboratory site on the accuracy of the APTT-based heparin therapeutic range. Int J Lab Hematol 2012, 34: 614-620. 10.1111/j.1751-553X.2012.01445.x.
85. Cuker A: Unfractionated heparin for the treatment of venous thromboembolism: best practices and areas of uncertainty. Semin Thromb Hemost 2012, 38: 593-599.
86. Speer O, Schmugge M, Metzger C, Albisetti M: Reference ranges of coagulation tests. Methods Mol Biol 2013, 992: 85-96. 10.1007/978-1-62703-339-8_6.
87. Olson JD, Arkin CF, Brandt JT, Cunningham MT, Giles A, Koepke JA, Witte DL: College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998, 122: 782-798.
88. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI, American College of Chest P: Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133: 141S-159S. 10.1378/chest.08-0689.
89. Cuker A, Ptashkin B, Konkle BA, Pipe SW, Whinna HC, Zheng XL, Cines DB, Pollak ES: Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time. J Thromb Haemost 2009, 7: 80-86. 10.1111/j.1538-7836.2008.03224.x.
90. Despotis GJ, Avidan MS, Hogue CW Jr: Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 2001, 72: S1821-S1831. 10.1016/S0003-4975(01)03211-8.
91. Despotis GJ, Joist JH, Goodnough LT: Monitoring of hemostasis in cardiac surgical patients: impact of point-of-care testing on blood loss and transfusion outcomes. Clin Chem 1997, 43: 1684-1696.
92. Ferraris VA, Ferraris SP, Singh A, Fuhr W, Koppel D, McKenna D, Rodriguez E, Reich H: The platelet thrombin receptor and postoperative bleeding. Ann Thorac Surg 1998, 65: 352-358. 10.1016/S0003-4975(97)01348-9.
93. George JN, Pickett EB, Saucerman S, McEver RP, Kunicki TJ, Kieffer N, Newman PJ: Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986, 78: 340-348. 10.1172/JCI112582.
94. George JN, Shattil SJ: The clinical importance of acquired abnormalities of platelet function. N Engl J Med 1991, 324: 27-39. 10.1056/NEJM199101033240106.
95. Khuri SF, Wolfe JA, Josa M, Axford TC, Szymanski I, Assousa S, Ragno G, Patel M, Silverman A, Park M: Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J Thorac Cardiovasc Surg 1992, 104: 94-107.
96. Laffey JG, Boylan JF, Cheng DC: The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology 2002, 97: 215-252. 10.1097/00000542-200207000-00030.
97. Levy JH, Tanaka KA: Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003, 75: S715-S720. 10.1016/S0003-4975(02)04701-X.
98. Rinder CS, Bohnert J, Rinder HM, Mitchell J, Ault K, Hillman R: Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 1991, 75: 388-393. 10.1097/00000542-199109000-00002.
99. Rinder CS, Mathew JP, Rinder HM, Bonan J, Ault KA, Smith BR: Modulation of platelet surface adhesion receptors during cardiopulmonary bypass. Anesthesiology 1991, 75: 563-570. 10.1097/00000542-199110000-00004.
100. Sniecinski RM, Chandler WL: Activation of the hemostatic system during cardiopulmonary bypass. Anesth Analg 2011, 113: 1319-1333. 10.1213/ANE.0b013e3182354b7e.
101. Warren OJ, Smith AJ, Alexiou C, Rogers PL, Jawad N, Vincent C, Darzi AW, Athanasiou T: The inflammatory response to cardiopulmonary bypass: part 1-mechanisms of pathogenesis. J Cardiothorac Vasc Anesth 2009, 23: 223-231. 10.1053/j.jvca.2008.08.007.
102. Warren OJ, Watret AL, de Wit KL, Alexiou C, Vincent C, Darzi AW, Athanasiou T: The inflammatory response to cardiopulmonary bypass: part 2-anti-inflammatory therapeutic strategies. J Cardiothorac Vasc Anesth 2009, 23: 384-393. 10.1053/j.jvca.2008.09.007.
103. Blombaeck M, Blombaeck B, Wallen P: Determination of the level of heparin in the blood in the case of extracorporeal circulation during cardiac surgery. Rev Hematol 1955, 10: 45-54.
104. Young JA, Kisker CT, Doty DB: Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 1978, 26: 231-240. 10.1016/S0003-4975(10)63676-4.
105. Lobato RL, Despotis GJ, Levy JH, Shore-Lesserson LJ, Carlson MO, Bennett-Guerrero E: Anticoagulation management during cardiopulmonary bypass: a survey of 54 North American institutions. J Thorac Cardiovasc Surg 2010, 139: 1665-1666. 10.1016/j.jtcvs.2010.02.038.
106. Taneja R, Fernandes P, Marwaha G, Cheng D, Bainbridge D: Perioperative coagulation management and blood conservation in cardiac surgery: a Canadian survey. J Cardiothorac Vasc Anesth 2008, 22: 662-669. 10.1053/j.jvca.2008.02.005.
107. Saad EB, Costa IP, Costa RE, Inacio LA Jr, Slater C, Camiletti A, Moura Neto DG, Maldonado P, Camanho LE, Polanczky CA: Safety of ablation for atrial fibrillation with therapeutic INR: comparison with transition to low-molecular-weight heparin. Arq Bras Cardiol 2011, 97: 289-296. 10.1590/S0066-782X2011005000088.
108. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Natale A, Packer D: Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010, 3: 32-38. 10.1161/CIRCEP.109.859116.
109. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Packer D, Skanes A: Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005, 111: 1100-1105. 10.1161/01.CIR.0000157153.30978.67.
110. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, DiMarco J: 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol 2012, 33: 171-257. 10.1007/s10840-012-9672-7.
111. Jobes DR, Ellison N, Campbell FW: Limit(ation)s for ACT. Anesth Analg 1989, 69: 142-144.
112. Jude B, Lasne D, Mouton C, de Moerloose P: Monitoring of heparin therapy during extracorporeal bypass: what are the remaining questions? Ann Fr Anesth Reanim 2004, 23: 589-596. 10.1016/j.annfar.2004.02.047.
113. Hussein HM, Georgiadis AL, Qureshi AI: Point-of-care testing for anticoagulation monitoring in neuroendovascular procedures. AJNR Am J Neuroradiol 2012, 33: 1211-1220. 10.3174/ajnr.A2621.
114. Davidson SJ, Tillyer ML, Keogh J, Hall J, Kelleher AA: Heparin concentrations in neonates during cardiopulmonary bypass. J Thromb Haemost 2012, 10: 730-732. 10.1111/j.1538-7836.2012.04659.x.
115. Gehrie E, Laposata M: Test of the month: the chromogenic antifactor Xa assay. Am J Hematol 2012, 87: 194-196. 10.1002/ajh.22222.
116. Ignjatovic V, Newall F, Monagle P: Heparin concentrations in neonates during cardiopulmonary bypass: a rebuttal. J Thromb Haemost 2012, 10: 1972. 10.1111/j.1538-7836.2012.04796.x.
117. Long E, Pitfield AF, Kissoon N: Anticoagulation therapy: indications, monitoring, and complications. Pediatr Emerg Care 2011, 27: 55-61. quiz2-4 10.1097/PEC.0b013e31820461b1.
118. Jin J, Price E, Nguyen H, Krishnan G, Balise R, Bowen RA, Zehnder JL: Prolonged aPTT relative to Anti-Xa is associated with increased 30-day mortality in hospitalized patients treated with unfractionated Heparin. ASH Annual Meeting Abstracts 2011, 118: 1248.
119. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, Kher A, Aiach M, Fiessinger JN: Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-study group. Thromb Haemost 1994, 71: 698-702.
120. Boneu B, de Moerloose P: How and when to monitor a patient treated with low molecular weight heparin. Semin Thromb Hemost 2001, 27: 519-522. 10.1055/s-2001-17961.
121. Kovacs MJ, Keeney M, MacKinnon K, Boyle E: Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 1999, 21: 55-60. 10.1046/j.1365-2257.1999.00183.x.
122. Kitchen S, Iampietro R, Woolley AM, Preston FE: Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost 1999, 82: 1289-1293.
123. Leizorovicz A, Bara L, Samama MM, Haugh MC: Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis 1993, 23: 89-98.
124. Hacquard M, Perrin J, Lelievre N, Vigneron C, Lecompte T: Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with calibrated automated thrombography. Thromb Res 2011, 127: 29-34. 10.1016/j.thromres.2010.07.024.
125. Al Dieri R, Alban S, Beguin S, Hemker HC: Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J Thromb Haemost 2006, 4: 83-89.
126. Potze W, Arshad F, Adelmeijer J, Blokzijl H, van den Berg AP, Porte RJ, Lisman T: Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis. Br J Haematol 2013, 163: 666-673. 10.1111/bjh.12593.
127. Bechmann LP, Sichau M, Wichert M, Gerken G, Kroger K, Hilgard P: Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int 2011, 31: 75-82. 10.1111/j.1478-3231.2010.02358.x.
128. Lisman T, Porte RJ: Towards a rational use of low-molecular-weight heparin in patients with cirrhosis. Liver Int 2011, 31: 1063. 10.1111/j.1478-3231.2011.02489.x.
129. Senzolo M, Rodriguez-Castro KI, Rossetto V, Radu C, Gavasso S, Carraro P, Zerbinati P, Sartori MT, Simioni P: Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis. J Thromb Haemost 2012, 10: 1823-1829. 10.1111/j.1538-7836.2012.04824.x.
130. Tripodi A, Mannucci PM: The coagulopathy of chronic liver disease. N Engl J Med 2011, 365: 147-156. 10.1056/NEJMra1011170.
131. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO: VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141: e691S-e736S.
132. James A: Practice bulletin no. 123: thromboembolism in pregnancy. Obstet Gynecol 2011, 118: 718-729. 10.1097/AOG.0b013e3182310c4c.
133. McLintock C, Brighton T, Chunilal S, Dekker G, McDonnell N, McRae S, Muller P, Tran H, Walters BN, Young L: Recommendations for the diagnosis and treatment of deep venous thrombosis and pulmonary embolism in pregnancy and the postpartum period. Aust N Z J Obstet Gynaecol 2012, 52: 14-22. 10.1111/j.1479-828X.2011.01361.x.
134. Middeldorp S: How I, treat pregnancy-related venous thromboembolism. Blood 2011, 118: 5394-5400. 10.1182/blood-2011-04-306589.
135. Ni Ainle F, Wong A, Appleby N, Byrne B, Regan C, Hassan T, Milner M, Sullivan AO, White B, O'Donnell J: Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy. Blood Coagul Fibrinolysis 2008, 19: 689-692. 10.1097/MBC.0b013e32830b14ef.
136. Smith MP, Norris LA, Steer PJ, Savidge GF, Bonnar J: Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol 2004, 190: 495-501. 10.1016/S0002-9378(03)00953-0.
137. Gibson PS, Newell K, Sam DX, Mansoor A, Jiang X, Tang S, Ross S: Weight-adjusted dosing of tinzaparin in pregnancy. Thromb Res 2013, 131: e71-e75. 10.1016/j.thromres.2012.11.018.
138. Morange PE, Alessi MC: Thrombosis in central obesity and metabolic syndrome: mechanisms and epidemiology. Thromb Haemost 2013, 110: 669-680. 10.1160/TH13-01-0075.
139. Frederiksen SG, Hedenbro JL, Norgren L: Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg 2003, 90: 547-548. 10.1002/bjs.4068.
140. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE: Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009, 43: 1064-1083. 10.1345/aph.1L194.
141. Rowan BO, Kuhl DA, Lee MD, Tichansky DS, Madan AK: Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes Surg 2008, 18: 162-166. 10.1007/s11695-007-9381-y.
142. Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton RC: Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thromb Res 2010, 125: 220-223. 10.1016/j.thromres.2009.02.003.
143. Wang TF, Milligan PE, Wong CA, Deal EN, Thoelke MS, Gage BF: Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thromb Haemost 2014, 111: 88-93.
144. Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, Ball SP, Antman EM: Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 2002, 143: 753-759. 10.1067/mhj.2002.120774.
145. Goudable C, Saivin S, Houin G, Sie P, Boneu B, Tonthat H, Suc JM: Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure. Nephron 1991, 59: 543-545. 10.1159/000186641.
146. Cestac P, Bagheri H, Lapeyre-Mestre M, Sie P, Fouladi A, Maupas E, Leger P, Fontan B, Massip P, Montastruc JL: Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients. Drug Saf 2003, 26: 197-207. 10.2165/00002018-200326030-00005.
147. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM: Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003, 146: 33-41. 10.1016/S0002-8703(03)00121-2.
148. Siguret V, Pautas E, Fevrier M, Wipff C, Durand-Gasselin B, Laurent M, Andreux JP, d'Urso M, Gaussem P: Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000, 84: 800-804.
149. Mismetti P, Laporte-Simitsidis S, Navarro C, Sie P, d'Azemar P, Necciari J: Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost 1998, 79: 1162-1165.
150. Schmid P, Brodmann D, Odermatt Y, Fischer AG, Wuillemin WA: Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. J Thromb Haemost 2009, 7: 1629-1632. 10.1111/j.1538-7836.2009.03556.x.
151. Siguret V, Gouin-Thibault I, Pautas E, Leizorovicz A: No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudy. J Thromb Haemost 2011, 9: 1966-1972. 10.1111/j.1538-7836.2011.04458.x.
152. Bounameaux H, de Moerloose P: Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J Thromb Haemost 2004, 2: 551-554. 10.1111/j.1538-7933.2004.00648.x.
153. Harenberg J: Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes. J Thromb Haemost 2004, 2: 547-550. 10.1111/j.1538-7933.2004.00647.x.
154. Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D: Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004, 110: 392-398. 10.1161/01.CIR.0000136830.65073.C7.
155. Lim W, Dentali F, Eikelboom JW, Crowther MA: Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006, 144: 673-684. 10.7326/0003-4819-144-9-200605020-00011.
156. Newall F, Chan AK, Ignjatovic V, Monagle P, Perinatal, Paediatric Haemostasis Subcommittee of the S: Recommendations for developing uniform laboratory monitoring of heparinoid anticoagulants in children. J Thromb Haemost 2012, 10: 145-147. 10.1111/j.1538-7836.2011.04561.x.
157. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ, American College of Chest Physicians Antithrombotic T: Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141: 7S-47S. 10.1378/chest.1412S3.
158. Greene LA, Law C, Jung M, Walton S, Ignjatovic V, Monagle P, Raffini LJ: Lack of anti-factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children. J Thromb Haemost 2014. doi: 10.1111/jth.12641. [Epub ahead of print].
159. Smogorzewska A, Brandt JT, Chandler WL, Cunningham MT, Hayes TE, Olson JD, Kottke-Marchant K, Van Cott EM: Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing. Arch Pathol Lab Med 2006, 130: 1605-1611.
160. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E: Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010, 103: 815-825. 10.1160/TH09-03-0176.
161. Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M, American College of Chest P: Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141: e495S-e530S.
162. Arixtra® (fondaparinux): Monographie du Dictionnaire Vidal. 2012.
163. Nagler M, Haslauer M, Wuillemin WA: Fondaparinux - data on efficacy and safety in special situations. Thromb Res 2012, 129: 407-417. 10.1016/j.thromres.2011.10.037.
164. GlaxoSmithKline (GSK): Package Insert, Arixtra (Fondaparinux Sodium) Injection. Research Triangle Park, NC: GlaxoSmithKline (GSK); 2004.
165. Castellone DD, Van Cott EM: Laboratory monitoring of new anticoagulants. Am J Hematol 2010, 85: 185-187.
166. Cohen D: Dabigatran: how the drug company withheld important analyses. BMJ 2014, 349: g4670-g. 10.1136/bmj.g4670.
167. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L, Investigators R-L: The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014, 63: 321-328. 10.1016/j.jacc.2013.07.104.
168. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W: Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J Thromb Haemost 2013, 11: 756-760. 10.1111/jth.12149.
169. European Medicine Agency: Pradaxa: summary of product characteristics 2014. [updated 2014 Jul 17; cited 2014 Jul 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf.
170. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM: Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012, 107: 985-997. 10.1160/TH11-11-0804.
171. Van Blerk M, Bailleul E, Chatelain B, Demulder A, Devreese K, Douxfils J, Jochmans K, Mullier F, Wijns W, Soumali MR, Coucke W, Vernelen K, Van de Walle P: Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey. Thromb Haemost 2014., 112: [Epub ahead of print].
172. Lippi G, Salvagno GL, Ippolito L, Franchini M, Favaloro EJ: Shortened activated partial thromboplastin time: causes and management. Blood Coagul Fibrinolysis 2010, 21: 459-463. 10.1097/MBC.0b013e328338dbe8.
173. Kitchen CS: To bleed or not to bleed? Is that the question for the PTT? J Thromb Haemost 2005, 3: 2607-2611. 10.1111/j.1538-7836.2005.01552.x.
174. Eikelboom JW, Hirsh J: Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 2006, 96: 547-552.
175. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE: Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001, 119: 64S-94S. 10.1378/chest.119.1_suppl.64S.
176. Barrett YC, Wang Z, Frost C, Shenker A: Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010, 104: 1263-1271. 10.1160/TH10-05-0328.
177. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Lindahl TL: Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011, 9: 133-139. 10.1111/j.1538-7836.2010.04098.x.
178. Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogne JM: Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012, 130: 956-966. 10.1016/j.thromres.2012.09.004.
179. Douxfils J, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Dogne JM, Mullier F: Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013, 110: 723-731. 10.1160/TH13-04-0274.
180. Becker RC, Alexander JH, Newby LK, Yang H, Barrett Y, Mohan P, Wang J, Harrington RA, Wallentin LC: Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost 2010, 104: 976-983. 10.1160/TH10-04-0247.
181. Douxfils J, Chatelain C, Chatelain B, Dogne JM, Mullier F: Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013, 110: 283-294. 10.1160/TH12-12-0898.
182. Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, Yu Z, Shenker A, Barrett YC, Mosqueda-Garcia R, Lacreta F: Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 2013, 76: 776-786. 10.1111/bcp.12106.
183. Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou MH, Laporte S, Siguret V, Lecompte T: Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost 2014, 111: 240-248.
184. Barrett YC, Wang Z, Knabb RM: A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors. Clin Appl Thromb Hemost 2013, 19: 522-528. 10.1177/1076029612441859.
185. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A: Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010, 103: 1116-1127. 10.1160/TH09-11-0758.
186. Douxfils J, Dogne JM, Mullier F, Chatelain B, Ronquist-Nii Y, Malmstrom RE, Hjemdahl P: Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013, 110: 543-549. 10.1160/TH13-03-0202.
187. Stangier J, Feuring M: Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012, 23: 138-143. 10.1097/MBC.0b013e32834f1b0c.
188. Antovic JP, Skeppholm M, Eintrei J, Boija EE, Soderblom L, Norberg EM, Onelov L, Ronquist-Nii Y, Pohanka A, Beck O, Hjemdahl P, Malmström RE: Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol 2013, 69: 1875-1881. 10.1007/s00228-013-1550-4.
189. Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, Taylor JM, Whinna HC, Winkler AM, Moll S: Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013, 11: 1493-1502. 10.1111/jth.12308.
190. Nowak G, Ouml TZ: The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb 2003, 33: 173-183. 10.1159/000081505.
191. Gosselin RC, Dwyre DM, Dager WE: Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Ann Pharmacother 2013, 47: 1635-1640. 10.1177/1060028013509074.
192. Harenberg J, Kramer R, Giese C, Marx S, Weiss C, Wehling M: Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis 2011, 32: 267-271. 10.1007/s11239-011-0622-5.
193. Francart SJ, Hawes EM, Deal AM, Adcock DM, Gosselin R, Jeanneret C, Friedman KD, Moll S: Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost 2014, 111: 1133-1140. 10.1160/TH13-10-0871.
194. Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, Alexander JH: Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 2011, 32: 183-187. 10.1007/s11239-011-0591-8.
195. Harenberg J, Du S, Weiss C, Kramer R, Hoppensteadt D, Walenga J, The working party: methods to determine apixaban of the Subcommittee on Control of Anticoagulation of the International Society of T, Haemostasis: Report of the subcommittee on control of anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH. J Thromb Haemost 2014, 12: 801-804.